Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 11, Issue 6, Pages 559
Publisher
MDPI AG
Online
2021-06-16
DOI
10.3390/jpm11060559
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
- (2020) Dominique Levêque et al. CLINICAL PHARMACOKINETICS
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risk factors for distant Metastasis of patients with primary Triple Negative Breast Cancer
- (2019) Yi Yao et al. BIOSCIENCE REPORTS
- Molecular stratification within triple-negative breast cancer subtypes
- (2019) Dong-Yu Wang et al. Scientific Reports
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
- (2018) Jun Tian et al. BRITISH JOURNAL OF CANCER
- Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer
- (2017) Khaled Greish et al. JOURNAL OF DRUG TARGETING
- Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme
- (2017) Khaled Greish et al. JOURNAL OF DRUG TARGETING
- Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)
- (2017) Xiao-Long Qian et al. PLoS One
- Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer
- (2015) Ravi Thakur et al. Scientific Reports
- Target Modulation by a Kinase Inhibitor Engineered to Induce a Tandem Blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: The Concept of Type III Combi-Targeting
- (2015) Suman Rao et al. PLoS One
- Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
- (2014) Khaled Greish et al. International Journal of Nanomedicine
- Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
- (2013) Alex Y Chang et al. BMC CANCER
- The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
- (2012) Hiroshi Maeda et al. ADVANCED DRUG DELIVERY REVIEWS
- Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
- (2012) Ping Fan et al. EUROPEAN JOURNAL OF CANCER
- Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
- (2011) M. Campone et al. ANNALS OF ONCOLOGY
- Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
- (2011) Ayca Gucalp et al. Clinical Breast Cancer
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- A Perspective on Cancer Cell Metastasis
- (2011) C. L. Chaffer et al. SCIENCE
- Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy
- (2011) Hiroshi Yagata et al. Breast Cancer
- Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles
- (2010) Chunbai He et al. BIOMATERIALS
- Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype
- (2010) Junichi Kurebayashi et al. BMC CANCER
- Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
- (2010) Manmeet S. Ahluwalia et al. CANCER LETTERS
- Metabolism considerations for kinase inhibitors in cancer treatment
- (2010) Derek R Duckett et al. Expert Opinion on Drug Metabolism & Toxicology
- Molecular Stratification of Triple-Negative Breast Cancers
- (2010) C. M. Perou ONCOLOGIST
- Dasatinib synergizes with doxorubicin to block growth, migration and invasion of breast cancer cells
- (2009) C S Pichot et al. BRITISH JOURNAL OF CANCER
- The Role of Src in Solid Tumors
- (2009) D. L. Wheeler et al. ONCOLOGIST
- Targeting Src in breast cancer
- (2008) R. S. Finn ANNALS OF ONCOLOGY
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- Targeting Src signaling in metastatic bone disease
- (2008) John Araujo et al. INTERNATIONAL JOURNAL OF CANCER
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now